Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + chemotherapy + bevacizumab
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A three-drug combination regimen including **QL1706**, a bifunctional MabPair product containing two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), **platinum-based chemotherapy**, and **bevacizumab** (a VEGF inhibitor). QL1706 provides dual immune checkpoint inhibition with a relatively short half-life for the CTLA-4 component, designed to enhance antitumor immunity while reducing immune-related toxicity. Bevacizumab adds antiangiogenic activity, and chemotherapy contributes a cytotoxic effect. The combination aims to synergistically target tumor growth and the tumor microenvironment, and is being investigated primarily in advanced lung cancers such as non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC), including in those who have failed prior targeted therapies[1][3][8][9].
- Other names
- PSB205PSB-205PSB 205
02
Targets
VEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA
Beyond the preview
Go deeper on QL1706 + chemotherapy + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + chemotherapy + bevacizumab.